Core Viewpoint - Plus Therapeutics, Inc. (PSTV) experienced a significant share price increase of 170.1% following the FDA's conditional acceptance of the proprietary name "Reyobiq" for its lead therapeutic candidate, rhenium Re186 obisbemeda [1] Company Developments - The company will now use the proprietary name Reyobiq for all communications related to the previously adopted generic name rhenium Re186 obisbemeda [2] - Reyobiq is being developed as a novel injectable radiotherapy aimed at delivering targeted high-dose radiation for central nervous system tumors, potentially improving patient outcomes [2] - Plus Therapeutics is focusing on Reyobiq for treating leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) [4] - The FDA granted Orphan Drug Designation to Reyobiq for treating LM in lung cancer patients, a rare complication where cancer spreads to the cerebrospinal fluid [4] - Enrollment for the ReSPECT-LM phase I study has been completed, which will assess the safety and efficacy of Reyobiq in patients with LM [5] - The company is preparing for a phase II single-dose expansion study and a phase I multiple-dose study for Reyobiq in LM patients [5] - Reyobiq is also being evaluated in the phase I/II ReSPECT-GBM study for recurrent glioblastoma treatment [6] Market Performance - Over the past year, shares of Plus Therapeutics have declined by 26.2%, while the industry average has decreased by 6.7% [3]